drugset

drugset / Trial / NCT05861453

Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

NCT05861453 ↗

Phase 2 Completed 35 enrolled Afimmune

NaSingle-groupOpen-labelTreatment

Summary

To assess the pharmacokinetics, pharmacodynamics and safety of Epeleuton capsules in adult SCD patients who are aged ≥18 years.

Timeline

Start: 2024-01-10
Primary completion: 2026-01-21
Completion: 2026-02-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Epeleuton	Unknown	2000 mg	Oral

Indications